Lipocine Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products. Its portfolio includes LPCN 1154 for postpartum depression, LPCN 2101 for epilepsy, LPCN 1148 for decompensated cirrhosis, and other partnering-focused candidates. TLANDO is its FDA-approved testosterone therapy.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue, net | $(3.122) million | $0 | $(3.067) million | $0.500 million |
| Research and development | $2.879 million | $2.100 million | $8.500 million | $6.886 million |
| General and administrative | $1.043 million | $0.799 million | $3.770 million | $3.172 million |
| Net loss | $(6.651) million | $(2.409) million | $(14.070) million | $(8.529) million |
| Cash used in operations | Not provided for quarter | $(9.844) million | $(10.130) million |
- Q3 and nine-month revenue include a noncash $3.1 million reversal of Antares minimum-guaranteed-royalty revenue. Excluding this reversal, revenue was limited; the company reported $55,000 of related-party license revenue from Spriaso in the first nine months.
- At September 30, cash and cash equivalents were $4.073 million and marketable securities were $19.775 million, totaling approximately $23.8 million in unrestricted liquid resources. Total assets were $24.752 million; current liabilities were $2.241 million and total liabilities were $2.271 million.
- The company reported no outstanding debt; its SVB loan was repaid in 2022. Nine-month investing cash inflow of $10.358 million largely reflected maturities of marketable securities. ATM stock sales provided approximately $410,000 net in 2023.
- Basic loss per share was $1.26 for Q3 and $2.68 for the first nine months, compared with $0.46 and $1.63, respectively, in 2022. Operating margins are not meaningful given the company’s losses and negative reported revenue.
Material changes and developments
- On October 2, 2023, Antares notified Lipocine that it would terminate the TLANDO license effective January 31, 2024. TLANDO rights are expected to revert to Lipocine. Lipocine plans to seek a new U.S. commercialization partner, but none is assured; the company does not expect material future revenue from Antares after termination.
- Losses increased year over year, principally as operating expenses rose while revenue included the Antares reversal. Nine-month R&D increased $1.614 million, driven in part by LPCN 1154 studies, TLANDO manufacturing, and the LPCN 1148 study.
- The company sold 81,000 shares through its ATM program during the first nine months for approximately $410,000 net. The filing says the Form S-3 registration currently permits up to $15.7 million of offering, subject to applicable limits. Shares outstanding were 5,315,830 as of November 6, 2023.
- A 1-for-17 reverse stock split took effect in May 2023; share and per-share amounts in the filing reflect the split.
Outlook, commentary and risks
- Management estimates existing capital resources and interest will fund its projected operating requirements through at least November 8, 2024, including ongoing LPCN 1148 and LPCN 1154 work and regulatory compliance. This estimate depends on assumptions; management says additional capital will be needed at some point. Failure to raise funds could threaten continued operations and force reductions or delays to development programs.
- After an October 18, 2023 FDA meeting, Lipocine said the FDA agreed with a 505(b)(2) NDA approach for LPCN 1154 based on one pivotal pharmacokinetic study. The company anticipated starting that study in Q1 2024 and reporting topline results in Q2 2024.
- Lipocine reported that its LPCN 1148 Phase 2 study met its primary endpoint in July 2023, with reported improvements in certain clinical outcomes and tolerability similar to placebo. The study’s open-label extension was ongoing.
- Key risks include reliance on future financing and partnering; clinical, regulatory and manufacturing uncertainty; TLANDO’s loss of its existing licensee and required post-marketing studies; and competition, including the announced launch of oral postpartum-depression treatment Zurzuvae. Management also cites potential volatility and Nasdaq listing-compliance risks.
- The company reported that the shareholder class-action lawsuit was dismissed with prejudice in April 2023. Management said it did not believe other legal matters would materially adversely affect its financial condition, liquidity or results. Disclosure controls were deemed effective as of September 30, 2023.
Important facts for investors to verify
- Whether Lipocine secures a TLANDO commercialization partner before or after the Antares agreement ends, and who will assume related post-marketing obligations.
- Actual cash burn and whether available funds remain sufficient for the planned LPCN 1154 and LPCN 1148 work through the stated runway date.
- Whether the LPCN 1154 pivotal study begins on schedule and achieves results supporting the proposed regulatory pathway.
- How much additional funding is required, and whether it comes from ATM sales, other financing, or licensing arrangements and on what terms.
- Progress and results from LPCN 1148’s extension study and other pipeline programs, including any changes in development plans or spending.